Genitourinary Cancers

The NMPA of China has approved toripalimab plus axitinib for use in the first-line treatment of patients with medium- to high-risk unresectable or metastatic RCC.

Samer A. Srour, MB ChB, MS, discusses efficacy and safety data for the allogeneic CAR T-cell therapy CTX130 in advanced clear cell renal cell carcinoma.

The anti-CD70 CAR T-cell therapy CTX130 showed activity and manageable toxicities in advanced renal cell carcinoma.

Wenxin (Vincent) Xu, MD, discusses ongoing efforts to identify new biomarkers in metastatic renal cell carcinoma.

The expert panel gives an overview of non–clear cell renal cell carcinoma, highlighting disease subtypes and treatment approaches.

Following a review of research on belzutifan in the advanced RCC space, the expert panel has a comprehensive discussion on treatment approaches and toxicity management.

Petros Grivas, MD, PhD, discusses potential future directions for adjuvant therapies in patients with resected renal cell carcinoma.

Stereotactic ablative body radiotherapy elicited high local control rates in patients with renal cell carcinoma who did not undergo surgical resection.

NICE has recommended the combination of cabozantinib and nivolumab for adult patients with advanced renal cell carcinoma in a final draft guidance.

Durvalumab in combination with guadecitabine was tolerable and led to a PFS benefit in patients with checkpoint inhibitor-naive ccRCC.

Wenxin (Vincent) Xu, MD, shares recent updates in the treatment of renal cell carcinoma, including insights into ongoing research and trials within the space.

Elizabeth Plimack, MD, MS, FASCO, recaps the discussion with key takeaways on recent updates in bladder cancer.

Wenxin (Vincent) Xu, MD, discusses the evolving landscape of systemic therapy in RCC, sharing how he makes treatment decisions amid the changing treatment space.

Marijo Bilusic, MD, PhD, discusses combination regimens under investigation for patients with non–clear cell renal cell carcinoma.

Focusing on belzutifan, Laurence Albigès, MD, PhD, reviews data from the LITESPARK-005 clinical trial, and Martin H. Voss, MD, discusses the ongoing LITESPARK-011 trial.

Experts on advanced RCC discuss the CONTACT-03 trial evaluating atezolizumab plus cabozantinib following immune checkpoint inhibitor treatment in patients with inoperable disease.

Jaime R. Merchán, MD, discusses the current roles for immunotherapy and TKIs in patients with renal cell carcinoma.

Wenxin (Vincent) Xu, MD, highlights research in renal cell carcinoma, spotlighting developments and updates in patients with non-clear cell disease.

Wenxin (Vincent) Xu, MD, on evolving systemic therapy and the utilization of biomarkers in the treatment of renal cell carcinoma.

Experts on bladder cancer discuss exciting new agents and treatment strategies and where they can potentially fit into urothelial cancer treatment paradigms.

Focusing on metastatic urothelial carcinoma, the panel discusses the role of chemotherapy and outlines treatment sequencing approaches.

Wenxin (Vincent) Xu, MD, discusses treatment decision-making in patients with renal cell carcinoma.

David A. Braun, MD, PhD, provides clinical insights on factors that influence treatment decisions in the second line and beyond for patients with advanced clear cell RCC.

Focusing on the LITESPARK-003 and LITESPARK-024 trials, Laurence Albigès, MD, PhD, discusses novel doublet regimens under investigation in the first-line setting in advanced renal cell carcinoma.

Evan Y. Yu, MD, provides insights on treatment approaches for patients with metastatic urothelial carcinoma in the second line and beyond.